Deuterated analogs of acetyl-leucine
US12145899B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 6, 2019 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Dec 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B59/001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined as set forth in the specification, and the deuterium enrichment of any one or more of R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is about 15% or more. The present disclosure also provides compounds having Formula I for use to treat or delay the progression of a lysosomal storage disorder or a neurodegenerative disease in a subject, provide neuroprotection in a subject having a lysosomal disorder, treat or prevent a migraine, and the symptoms associated therewith, in a subject, or improve mobility and/or cognitive function in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.